228 related articles for article (PubMed ID: 36803278)
1. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract][Full Text] [Related]
2. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
4. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
5. Investigational drugs for the treatment of cervical cancer.
Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
[TBL] [Abstract][Full Text] [Related]
6. What's the latest with investigational drugs for soft tissue sarcoma?
Cojocaru E; Napolitano A; Fisher C; Huang P; Jones RL; Thway K
Expert Opin Investig Drugs; 2022 Nov; 31(11):1239-1253. PubMed ID: 36424693
[TBL] [Abstract][Full Text] [Related]
7. Combinational therapies for the treatment of advanced cervical cancer.
Duenas-Gonzalez A
Expert Opin Pharmacother; 2023 Jan; 24(1):73-81. PubMed ID: 35653267
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
9. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
[TBL] [Abstract][Full Text] [Related]
10. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
11. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
[TBL] [Abstract][Full Text] [Related]
12. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
13. Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review.
Koshkin VS; Osbourne AS; Grivas P
Transl Androl Urol; 2021 Oct; 10(10):4022-4035. PubMed ID: 34804845
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Turinetto M; Valsecchi AA; Tuninetti V; Scotto G; Borella F; Valabrega G
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408919
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
[No Abstract] [Full Text] [Related]
16. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
Giudice E; Mirza MR; Lorusso D
Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
19. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
20. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
